FRα (Folate receptor-alpha)

Product List

Our team of experts has extensive experience in the design and optimization of anti-FRα CAR constructs. Please browse the list below to find the product you want. We also customize our products to meet your specific needs.

Background

Folate receptor-alpha (FRα), also known as FOLR1, FBP, FOLR, FR1, is a glycosylphosphatidyl-inositol-linked protein encoded by the FOLR1 gene. This receptor is a membrane-bound protein with a high affinity for binding and transporting physiologic levels of folate into cells. Compared to normal cells, FRα is overexpressed on ovarian and several other epithelial malignancies including renal cancer, lung cancer, and breast cancer. Therefore, FRα can be used as a target for imaging and therapy.

Associated Disease

Ovarian cancer

Renal cancer

Lung cancer

Breast cancer

Others

Anti-FRα CAR-T Services

Anti-FRα CAR-T In Vitro Assays

Anti-FRα CAR-T Expression Test

At Creative Biolabs, our CAR-T cell proliferation service not only offers innovative CAR detection reagents but also provides a comprehensive range of assay services to support your research projects. For example, flow cytometry is a common tool to evaluate Anti-FRα CAR expression at the single-cell level, providing quantitative and qualitative information.

Fig.1 Evaluation of anti-FRα CAR expression. The results show primary human CD3 T cells can efficiently express FRα-specific CAR.¹

Anti-FRα CAR-T Cytokine Release Test

The cytokine release test not only provides valuable insights into the safety and efficacy of the final product but also helps identify potential side effects or toxicities associated with the treatment. Our comprehensive cytokine release test services offer a comprehensive and sensitive approach for measuring these key cytokines, such as TNF-α and IFN-γ.

Fig.2 IFN-γ secretion by anti-FRα CAR-T cells co-cultured with FRα+ cancer cell lines. The anti-FRα CAR-T cells secreted high levels of IFN-γ.²

Anti-FRα CAR-T In Vitro Cytotoxicity Assay

We offer cytotoxicity assay services to support the evaluation of anti-FRα CAR-T cell therapy. We utilize various cytotoxicity assays including radioactive chromium release assay, bioluminescence, and flow cytometry to test in vitro antitumor efficacy.

Fig.3 Cytolytic activity of anti-FRα CAR-T cells against FRα- C30 cell and FRα+ MDA-231 cells. anti-FRα CAR-T cells exhibited antigen-specific killing of FRα+ tumor cells.¹

Anti-FRα CAR-T In Vivo Assays

Efficacy Test of Anti-FRα CAR-T

Creative Biolabs uses various tools and technologies to study the in vivo biology of anti-FRα CAR-T cells. We assess the antitumor activity of anti-FRα CAR-T cells against FRα+ cancer cells in mouse models.

Fig.4 In vivo anti-tumor activity of anti-FRα CAR-T cells. Anti-FRα CAR-T cells induce rapid tumor regression of MDA-231 in vivo.¹

Toxicity Evaluation Anti-FRα CAR-T

At Creative Biolabs, we offer a comprehensive solution for the evaluation of CAR-T cell toxicity to ensure the safety and efficacy of the final product. We provide a range of in vivo toxicity study services to support your CAR-T research projects. These services include tumorigenicity study, tumor lysis analysis, on-target toxicity, and off-target toxicity.

References

1. Song, De-Gang, et al. "Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level." Journal of hematology & oncology 9.1 (2016): 1-12.
2. Song, De-Gang, et al. "In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)." Cancer research 71.13 (2011): 4617-4627.